• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    TG Therapeutics Stock Gets A New Test After Early CAR T And Long Term MS Data

    Simply Wall St·11/01/2026 04:42:41
    語音播報
    • TG Therapeutics reported initial Phase 1 data for azer-cel in progressive multiple sclerosis and seven-year clinical and real-world BRIUMVI results at MSToronto2026, highlighting safety, disability measures and treatment experience across its MS portfolio.
    • The pairing of early azer-cel findings with durable BRIUMVI outcomes underscores TG Therapeutics’ effort to translate MS research assets into a broader, potentially more resilient neurology business.
    • The focus now turns to how these BRIUMVI durability data and the first azer-cel readout could influence TG Therapeutics’ investment narrative.

    Scan how TG Therapeutics fits into the wider neurology opportunity set by lining it up against a hand picked 34 healthcare AI stocks that are also pushing the frontier in brain and immune disorders.

    TG Therapeutics Investment Narrative Recap

    To own TG Therapeutics, you need to believe BRIUMVI can support a durable MS franchise while the subcutaneous program and broader autoimmune plans turn current revenue into consistent, high margin earnings. The recent MSToronto2026 data mainly reinforces that operating story. The nearer term swing factor still looks like execution on BRIUMVI growth and cost discipline rather than a single trial headline.

    The biggest operational risk remains spending and manufacturing investments outpacing what BRIUMVI and future launches can support, especially after a quarter where higher expenses hurt earnings against expectations. Governance questions and any stumble in subcutaneous BRIUMVI, secondary manufacturing or pipeline uptake could quickly change how dependable TG Therapeutics’ cash generation looks.

    The seven year ULTIMATE BRIUMVI update at MSToronto2026 is the clearest near term operational piece for TG Therapeutics. Long duration efficacy and disability data help management argue that BRIUMVI can be the anchor product while subcutaneous and new indications are pursued, which matters if the business is going to support over US$100 million of planned 2026 manufacturing spend.

    Those trial results also connect directly to upcoming catalysts like the ENHANCE based label change for a single 600 mg infusion and the fully enrolled Phase 3 subcutaneous program. If physicians and payers view the long term profile as robust, that can support adoption of simpler dosing and, later, self administered BRIUMVI, which would test how well the company converts clinical data into real world operating leverage.

    What The Current TG Therapeutics Forecasts Assume

    Analysts sketch a TG Therapeutics story that leans heavily on both BRIUMVI execution and disciplined spending. The numbers behind that view matter if you are trying to judge how much of the MS and autoimmune ambition is already reflected in the stock price.

    On the top line, the consensus framework assumes revenue climbs at about 30.2% a year over the next three years. That is a steep ramp for any commercial stage biotech, so it effectively asks you to accept that the BRIUMVI franchise and emerging autoimmune efforts support sustained expansion from today’s base.

    Profitability expectations tell a different story. Analysts currently model profit margins sliding from 55.2% today to 35.1% in three years. That pullback lines up with the higher manufacturing and pipeline spend already visible in quarterly reports and underlines why the balance between growth investment and cost control remains so important for this ticker.

    On earnings, current consensus points to TG Therapeutics producing US$441.5 million today and US$619.2 million by 2029. That is an increase of about US$178 million over the period, with the more optimistic forecasts reaching as high as US$762.4 million. The spread between those scenarios shows how much disagreement there still is around the eventual profitability of the broader BRIUMVI platform.

    Valuation assumptions build directly on those figures. For the analyst price targets to stack up, the stock would need to trade on a P/E of 18.2x in 2029, compared with 17.4x today and a current US Biotechs industry level of about 17.2x. That premium is not extreme on its own, but it does hinge on the company hitting both the revenue and earnings path that the consensus has laid out despite pressure on margins.

    Share count projections also feed into the equity story. Forecasts currently bake in a 2.98% annual decline in outstanding shares over the next three years, consistent with the active repurchase activity already disclosed. If that continues, per share earnings outcomes could improve faster than absolute profit, although the benefit only holds if cash returned to investors does not undercut investment in the pipeline that supports those future earnings.

    All of these moving parts are then discounted back to today using a 7.69% rate in the Simply Wall St framework, which is rounded to 7.7% in the analyst target narrative. The result is a consensus price target of US$69.71 per share versus a current price reference of US$54.29, leaving about 22.1% implied upside in that model. The most optimistic targets sit at US$86 while the lowest land near US$21, a range that highlights how sensitive any view on TG Therapeutics still is to assumptions about spending, governance outcomes and the eventual shape of the BRIUMVI franchise.

    TG Therapeutics' current consensus path points to revenue of about US$1.8b and earnings of US$619.2 million by 2029, which implies roughly 30.2% yearly revenue growth and an earnings increase of about US$178 million from US$441.5 million today.

    Uncover why TG Therapeutics' fair value indicates a 14% potential upside to its current price that could narrow quickly.

    NasdaqCM:TGTX 1-Year Stock Price Chart
    NasdaqCM:TGTX 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate storyline puts azer cel at the center. Bullish analysts were already penciling in about US$2.2b of revenue and around US$761.4 million of earnings by 2029 before this early CAR T update. You can see how that more optimistic view could strengthen if Phase 1 MS data hold up, or soften if follow up disappoints.

    Explore 4 other TG Therapeutics fair value estimates, including one that suggests as much as 188% potential upside from the current price.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond TG Therapeutics?

    Once you have a view on TG Therapeutics, it can help to widen the lens and test your thesis against other businesses with different risk and return profiles. The Simply Wall St Screener lets you do that quickly by filtering for traits that matter to you, whether that is quality, balance sheet strength or income.